BCL2 and rheumatoid arthritis: Preliminary clinical studies have shown that XFC promotes CD4+T cell apoptosis in RA patients by upregulating the expression of pro-apoptotic proteins (Fas, FasL, caspase-8, and caspase-3) and downregulating the expression of anti-apoptotic protein Bcl-2 (24).